Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Target-specific oral anticoagulants in atrial fibrillation: results of phase III trials and comments on sub-analyses.

Mantha S.

J Thromb Thrombolysis. 2013 Aug;36(2):155-62. doi: 10.1007/s11239-013-0925-9. Review.

PMID:
23595515
2.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
3.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
4.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
5.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
6.

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C.

J Thromb Haemost. 2012 Oct;10(10):1979-87. doi: 10.1111/j.1538-7836.2012.04866.x. Review.

7.

Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Harris K, Mant J.

Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28. Review.

8.

The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis.

Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, Drost P.

Clin Appl Thromb Hemost. 2013 Nov-Dec;19(6):619-31. doi: 10.1177/1076029613486539. Epub 2013 May 22. Review.

PMID:
23698729
9.

Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

Deedwania PC, Huang GW.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):265-75. doi: 10.2165/11592410-000000000-00000. Review.

PMID:
21740079
10.

Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.

Cope S, Clemens A, Hammès F, Noack H, Jansen JP.

Value Health. 2015 Mar;18(2):234-49. doi: 10.1016/j.jval.2014.10.012. Epub 2015 Jan 28. Review.

11.

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.

Baker WL, Phung OJ.

Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):711-9. Epub 2012 Aug 21. Review.

12.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
13.

Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

Yates SW.

Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Review.

PMID:
22056819
14.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
15.
16.

Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.

Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB.

Clin Res Cardiol. 2015 May;104(5):418-29. doi: 10.1007/s00392-014-0797-9. Epub 2014 Nov 22. Review.

PMID:
25416564
17.

Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.

Liew A, Eikelboom JW, O'Donnell M.

Curr Opin Cardiol. 2012 Jul;27(4):331-9. doi: 10.1097/HCO.0b013e3283540857. Review.

PMID:
22573171
18.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498
19.

A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.

Hess CN, Al-Khatib SM, Granger CB, Lopes R.

Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1105-14. doi: 10.1586/14779072.2013.824181. Epub 2013 Sep 2. Review.

PMID:
23992517
20.

New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.

Coccheri S, Orlando D.

Intern Emerg Med. 2013 Mar;8(2):115-22. doi: 10.1007/s11739-012-0886-6. Epub 2012 Dec 18. Review. Erratum in: Intern Emerg Med. 2013 Sep;8(6):547.

PMID:
23247681
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk